Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Methylprednisolone and Rituximab in High Risk B-CLL
NCT00558181Phase 2Completed
- Sponsor
- Vilnius University
- Start
- Sep 2007
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, methylprednisolone injection in chronic lymphocytic leukemia (CLL), sponsored by Vilnius University. Started Sep 2007; status: completed.
02
Drugs
rituximabmethylprednisolone injection
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00558181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558181.